Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

160.40B

Market cap160.40B

Price-Earnings ratio

18.84

Price-Earnings ratio18.84

Dividend yield

2.50%

Dividend yield2.50%

Average volume

5.50M

Average volume5.50M

High today

$130.47

High today$130.47

Low today

$128.34

Low today$128.34

Open price

$130.33

Open price$130.33

Volume

5.94M

Volume5.94M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$95.30

52 Week low$95.30

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $128.39, giving the company a market capitalization of 160.4B. It carries a P/E multiple of 18.84 and pays a dividend yield of 2.5%.

During the trading session on 2026-04-28, Gilead Sciences(GILD) shares reached a daily high of $130.47 and a low of $128.34. At a current price of $128.39, the stock is +0.0% higher than the low and still -1.6% under the high.

Trading activity shows a volume of 5.94M, compared to an average daily volume of 5.5M.

The stock's 52-week range extends from a low of $95.30 to a high of $157.29.

GILD News

Barron's 10h

Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here.

Technical Analysis Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. In this article GILD XBI IBB Gilead headquarters in Foster...

TipRanks 11h

Gilead Sciences Completes Acquisition of Arcellx and Anito-cel

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 12h

Gilead completes acquisition of Arcellx for $115 per share in cash

Gilead Sciences (GILD) announced the completion of its previously announced acquisition of Arcellx (ACLX). Under the terms of the transaction, Gilead acquired A...

Analyst ratings

75%

of 32 ratings

Buy

75%

Hold

21.9%

Sell

3.1%

More GILD News

Benzinga 6d

What's Going On With Arcus Biosciences Stock On Wednesday?

In an SEC filing after hours on Monday, the company said it has discontinued its Phase 3 STAR-121 study in metastatic non-small cell lung cancer after an interi...

Simply Wall St 7d

Assessing Gilead Sciences Valuation After Recent Share Price Weakness And Long Term Gains

Advertisement Why Gilead Sciences (GILD) Is Drawing Investor Attention Now With no single headline event driving the move, Gilead Sciences (GILD) is attractin...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.